Topper先生最初於2020年加入Frazier生命科學團隊，擔任資深顧問，目前擔任Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC)的財務長。他曾擔任泛大西洋資本集團(General Atlantic)的全球資本市場負責人。在加入泛大西洋資本集團前，他曾擔任摩根大通的股票資本市場共同主管，負責公司的重大諮詢和融資交易，並與美國財政部和其他監管機構就危機相關問題展開合作。他還曾擔任摩根大通承諾委員會主席。在此之前，Topper先生曾在摩根士丹利工作長達22年，擔任美國股權資本市場共同主管、董事總經理及股權承諾委員會主席等職務。在職業生涯早期，他曾在摩根士丹利的債務資本市場、槓桿融資和併購部門擔任過其他幾個資深管理職務。Menlo Park, Calif.-- (BUSINESS WIRE)-- (business news)-- Frazier Healthcare Partners today announced the promotion of four life science team members: Jamie Brush, M.D. Promoted to general partner and portfolio manager, David Topper to capital markets partner, Liz Park to head of investor relations, and Joe Cabral to senior manager.
Dr. Brush joined the Frazier Life Sciences (Frazier Life Sciences) team in 2016 to co-lead Frazier's public equity investment strategy. He is a co-portfolio manager at the Frazier Public Fund for Life Sciences (Frazier Life Sciences Public Fund). The Frazier Life Sciences Public Fund is a $830 million long-term fund that invests in small and medium-sized listed biotechnology companies. He has led Frazier's IPO investments in Trillium Therapeutics (NASDAQ: TRIL; to be acquired by Pfizer Inc), Translate Bio (NASDAQ: TBIO; to Sanofi Pasteur), Iveric Bio (NASDAQ: ISEE), Rocket Pharmaceuticals (NASDAQ: RCKT), Krystal Biotech (NASDAQ: KRYS), and co-led Frazier's investment in ARMO (NASDAQ: ARMO; acquired by Eli Lilly and Co) and Ignyta (NASDAQ: RXDX; acquired by Roche). In addition, Dr. Brush joined the boards of Amunix Pharmaceuticals and Dascena on behalf of Frazier.
Mr. Topper first joined the Frazier Life Sciences team in 2020 as a senior consultant and is currently Chief Financial Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC). He was the global head of capital markets for the Pan-Atlantic Capital Group (General Atlantic). Prior to joining Pan-Atlantic Capital Group, he served as co-head of equity capital markets for JPMorgan Chase & Co, responsible for the company's major advisory and financing transactions, and worked with the US Treasury and other regulators on crisis-related issues. He also served as chairman of the JPMorgan Chase & Co commitment Committee. Prior to that, Mr. Topper worked at Morgan Stanley for 22 years, serving as co-head of US equity capital markets, managing director and chairman of the Equity commitment Committee. Early in his career, he held several other senior management positions in Morgan Stanley's debt capital markets, leveraged finance and mergers and acquisitions departments.
Ms. Park first joined the Frazier Life Sciences team in 2003 to help set up the Bay Area office and interface with Frazier's portfolio company. She rejoined the company in 2015, responsible for investor relations and communication, marketing and fund-raising, and public relations. Prior to joining Frazier, Ms. Park worked as a product project manager in the global regulatory affairs and security department of Amgen Inc (Amgen) and as an assistant project manager at MacuSight.
Mr. Cabral joined the Frazier Life Sciences team in 2021, focusing on discovering, evaluating and building new venture capital. Prior to joining Frazier, he worked on building venture capital at Flagship Pioneering, helping leading life science companies develop science, intellectual property rights and corporate strategies. After completing Flagship's Fellows project in 2018, Mr. Cabral played a key role in the establishment and development of Generate Biomedicines. Mr. Cabral has held operational positions in biology and corporate strategy for Generate Biomedicines, a platform company that uses machine learning for protein design. Prior to joining Flagship, Mr. Cabral was an early employee of Moderna Inc, where Moderna Inc helped expand the computational biology department and led research activities to better understand the biophysics of modified mRNA and helped launch personalized cancer vaccine treatment projects.
Patrick Heron, managing partner of Frazier's life sciences team, said: "We are very pleased to see the growth of the company's team. Jamie, David, Liz and Joe have played an important role in Frazier's public and private investment strategies in life sciences, and we look forward to their continued contribution. "
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. Frazier has raised more than $7.1 billion in capital and has invested in more than 200 companies, ranging from start-ups and start-ups to listed companies and acquisitions of profitable mid-and low-end companies. The Frazier Life Sciences team, headquartered in Menlo Park, Calif., invests globally in private and public companies that develop and commercialize innovative biopharmaceuticals to address important and unmet medical needs. Since 2005, 61 Frazier Life Sciences portfolio companies have completed initial public offerings or mergers and acquisitions, many of which were founded or incubated by Frazier.
For more information about Frazier Life Sciences, please visit the company's website at www.frazierhealthcare.com/life-sciences.
Disclaimer: the original version of this announcement is officially authorized. The translation is for easy understanding only. Please refer to the original text, which is the only version with legal effect.
Contacts
Cogenta Communications (stands for Frazier Healthcare Partners)
Theresa Maloney
Tel: 415.225.5261
Email: theresa@cogentacom.com
Frazier Healthcare Partners
Kate Schykerynec
Tel: 650.325.5156
Email: kate@frazierhealthcare.com